Bacterial Endotoxin Testing by LAL
GMP/GLP compliant testing laboratory, Wickham Laboratories Ltd, offers a dedicated in vitro bacterial endotoxin service for clients requiring biocompatibility testing.
Wickham Laboratories offers biocompatibility assessment via the Limulus Amebocyte Lysate (LAL) method to those of our clients requiring bacterial endotoxin screening. With over 20 years of experience in bacterial endotoxin testing, we are uniquely equipped to deal with your challenging and complicated samples, including cytotoxics.
LAL is an established in vitro test for the screening of parenteral medicines, irrigation fluids, dialysis solutions, purified water and medical devices. We offer all three standard LAL methods: gel clot, kinetic chromogenic and kinetic turbidimetric, working closely with our clients to determine which method is best for their particular requirements.
As a GMP/GLP compliant laboratory with over 50 years of experience, we are an established name in the fields of pharmaceutical and medical device contract testing, research and consultancy. We are routinely inspected by the MHRA, FDA and Home Office and maintain an audit ready facility at all times.
Conducting business with clients worldwide, the combined expertise of our laboratory technicians and managers enables us to be fully conversant with global regulatory expectations. For more information about Wickham Laboratories Limited and our services, please contact us at +44 (0)1329 226600 or mail@wickhamlabs.co.uk.
Contact Details:
Wickham Laboratories Ltd
Website: www.wickhamlabs.co.uk
E-mail: mail@wickhamlabs.co.uk
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
